<DOC>
	<DOCNO>NCT00510354</DOCNO>
	<brief_summary>The purpose multicenter , single-arm , Simon two-stage , phase II trial determine efficacy safety everolimus combination Imatinib mesylate patient previously treat , histologically proven GIST whose disease recur progressed receive 400 mg/day Imatinib mesylate time least 2 month ' treatment period .</brief_summary>
	<brief_title>Treatment Patients With Everolimus Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors ( GIST ) Are Resistant Imatinib Mesylate</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : 1 . Histological proven diagnosis GIST 2 . Objectively documented evidence progressive disease accord RECIST criterion despite least 2 month ' continuous treatment Imatinib mesylate dosage 400 mg/day 3 . Clinical evidence resistance Imatinib mesylate treatment 400 mg/day Imatinib 4 . Progression must document CT MRI scan . The scan progression document maximum 2 week old . New scan require baseline scan older approx . 2 week 5 . At least one measurable lesion ( long diameter ≥ 20 mm conventional CT MRI scan ; ≥ 10 mm spiral CT ) 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 7 . Adequate bone marrow , liver renal function Imatinib treatment 8 . Patients must least 4 week since prior major surgery recover , least 2 week since prior minor surgery recover Exclusion criterion : 1 . Female patient pregnant breast feeding , patient reproductive potential employ effective method birth control . Because oral , implantable injectable contraceptive may affect cytochrome P450 interaction , appropriate method birth control use throughout trial sex . Women childbearing potential must negative serum pregnancy test ≤ 48 hour prior administration study medication 2 . Patients present know symptomatic CNS metastasis leptomeningeal involvement 3 . Use investigational cancer therapy within 28 day prior enrollment currently plan receive course study 4 . Patients previously receive rapamycin combination Imatinib 5 . Patients concurrent major medical condition liable compromise patient 's participation study ( e.g . know HIV infection , uncontrolled diabetes , serious cardiac dysrhythmia condition , New York Heart Association classification III IV , congestive cardiac failure , myocardial infarction within 6 month , unstable angina , chronic acute renal liver disease , uncontrolled infection include abscess fistula , etc . ) 6 . Patients history another malignancy within 5 year prior study entry , except curatively treat nonmelanotic skin cancer insitu cervical cancer 7 . Patients receive glucocorticoid ( p70s6 kinase1 assay perform ) , since glucocorticoid show inhibit p70s6 kinase1 activity Other protocol define inclusion/ exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Progressive GIST</keyword>
	<keyword>Resistance Imatinib mesylate</keyword>
</DOC>